ArticleCureus2025
Effect of Ketamine Supplementation in Axillary Plexus Blockade: A Comparative Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Axillary brachial plexus block is a widely used regional anesthesia technique for below-elbow surgeries. The use of adjuvant medications can influence block characteristics and postoperative pain experience. This randomized, prospective, single-blind comparative study aimed to evaluate whether ketamine, administered intravenously or regionally with ropivacaine, affects postoperative analgesia, rebound pain, and the onset time of sensory and motor block. Methods A randomized, prospective, single-blind comparative study was performed in patients undergoing ultrasound-guided axillary brachial plexus block for below-elbow surgery. Participants were assigned to three groups: group 1 (control, ropivacaine alone), group 2 (intravenous ketamine plus ropivacaine), or group 3 (regional ketamine plus ropivacaine). Onset of sensory and motor block, postoperative pain intensity using the numerical rating scale (NRS), need for rescue analgesia, and adverse effects during the first 24 hours were recorded and compared. Results The study included 81 patients (49 men and 32 women) with a mean age of 44.27±17.61 years (range: 16-81 years). Among them, 28 patients were in group 1, 27 patients in group 2, and 26 patients in group 3. Univariate analysis showed that both regional and intravenous ketamine administration were associated with faster onset of blockade (p<0.0005) and significantly lower NRS scores than the local anesthetic alone, at 16, 20, and 24 hours after the end of surgery (p=0.049, p=0.009, and p=0.006, respectively). No statistically significant difference was observed in motor block scores (p=0.329) and postoperative opioid (tramadol) intake (p=0.888) among the three groups. Conclusions Intravenous and regional addition of ketamine to ropivacaine solution improved postoperative analgesia equally by attenuating rebound pain and reducing the onset time of sensory and motor block. More high-quality studies are needed to fully elucidate the role of ketamine in axillary brachial plexus block.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.